文献速递贫血与红细胞疾病

老年再生障碍性贫血患者:真实世界中的治疗模式与结局

Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World.
PubMed 文献 · Am J Hematol · 2025-01-29

该回顾性国际队列纳入1113例再生障碍性贫血患者,评估老年患者与年轻人群的治疗选择与结局。老年患者一线治疗6个月总反应率显著低于年轻患者(47% vs 65%,p<0.0001),进展为MDS的比例更高(12% vs 7%,p=0.002),多因素分析显示年龄较大是与死亡相关的主要因素[HR 1.64(95%CI 1.5-1.7),p<0.001]。

要点

  • 老年(>60岁)患者一线治疗6个月总反应率显著低于年轻患者(47% vs 65%,p<0.0001)。
  • 老年患者进展为MDS的比例高于年轻患者(12% vs 7%,p=0.002),进展为AML的比例相似(1.8% vs 1.3%)。
  • 多因素分析显示年龄较大是与死亡相关的主要因素[HR 1.64(95%CI 1.5-1.7),p<0.001]。

核心结论

  • 在这项大型研究中,老年再生障碍性贫血患者即使处于TPO-RA时代仍与较差结局相关,突出需要进一步优化临床管理。

研究设计与样本

  • 回顾性分析大型国际队列1113例再生障碍性贫血患者,评估老年患者与年轻人群的治疗选择与结局。
  • 319例(29%)患者诊断时>60岁:60-64岁85例,65-69岁106例,>70岁128例。

主要发现

  • 老年患者起病时血小板减少更严重,一线治疗6个月总反应率(完全+部分)显著低于年轻患者(47% vs 65%,p<0.0001),与治疗方式(ATG或CyA联合、艾曲泊帕或雄激素)无关。
  • 27例(8%)老年患者接受移植作为二线治疗,其中11例(41%)死亡,主要死于移植并发症。
  • 老年患者进展为MDS的比例高于年轻AA患者(12% vs 7%,p=0.002),进展为AML的比例相似(1.8% vs 1.3%)。
  • 多因素分析显示年龄较大是与死亡相关的主要因素[HR 1.64(95%CI 1.5-1.7),p<0.001],其次是Camitta分级的疾病严重程度[重型AA HR 2.24(95%CI 1.6-3.1);极重型AA HR 3.8(95%CI 2.4-6)],以及男性[HR 1.45(95%CI 1.1-1.8),p<0.001]。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We retrospectively analyzed a large international cohort of 1113 patients with aplastic anemia to evaluate treatment choice and outcome in elderly patients as compared with a younger population. Overall, 319 (29%) patients were > 60 years old at diagnosis (60-64 years (n = 85), 106 65-69 years (n = 106), and 128 > 70 years (n = 128)). Elderly patients showed a more severe thrombocytopenia at onset and a significantly lower overall response (complete plus partial) to first-line therapy at 6 months as compared to younger patients (47% vs. 65%, p < 0.0001), irrespective of treatment modality (ATG or CyA combinations, eltrombopag, or androgens); 27 (8%) received transplant as second line therapy and 11 (41%) died, mainly due to transplant complications. The rate of evolution to MDS was greater in elderly patients (12% vs. 7% in younger AA, p = 0.002), whilst the rate of evolution to AML was similar (1.8 vs. 1.3%). By multivariable analysis, older age remained the main factor associated with mortality [HR 1.64 (95% CI 1.5-1.7), p < 0.001], followed by disease severity by Camitta classification [HR 2.24 (95% CI 1.6-3.1) for severe AA; HR 3.8 (95% CI 2.4-6) for very severe AA], and male gender [1.45 (95% CI 1.1-1.8), p < 0.001]. In this large study, elderly AA was associated with inferior outcome even in the TPO-RA era, highlighting the need for further optimization of clinical management.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Fattizzo B, Gurnari C, Giammarco S, et al. Elderly Patients With Aplastic Anemia: Treatment Patterns and Outcomes in the Real World. Am J Hematol. 2025. PMID: 39878088. doi:10.1002/ajh.27611

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。